The purpose of this study is to evaluate the safety, tolerability, and exposure-response (E-R) of BMS-986435/MYK-224 in participants with symptomatic Heart Failure with Preserved Ejection Fraction (HFpEF).
Heart Failure
The purpose of this study is to evaluate the safety, tolerability, and exposure-response (E-R) of BMS-986435/MYK-224 in participants with symptomatic Heart Failure with Preserved Ejection Fraction (HFpEF).
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
-
University of Alabama at Birmingham, Birmingham, Alabama, United States, 35233
Infinite Clinical Research, Miami, Florida, United States, 33133-4223
Local Institution - 0014, Atlanta, Georgia, United States, 30322-1013
Local Institution - 0048, Atlanta, Georgia, United States, 30322-1013
Bluhm Cardiovascular Institute of Northwestern, Chicago, Illinois, United States, 60611-5969
Chicago Medical Research, LLC, Hazel Crest, Illinois, United States, 60429-2196
Ascension Medical Group St. Vincent - Indianapolis Heart Care, Indianapolis, Indiana, United States, 46260-1992
Local Institution - 0045, Indianapolis, Indiana, United States, 46260-1992
St. Louis Heart and Vascular, Saint Louis, Missouri, United States, 63136-6111
Local Institution - 0043, Saint Louis, Missouri, United States, 63136
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
40 Years to 90 Years
ALL
No
Bristol-Myers Squibb,
Bristol-Myers Squibb, STUDY_DIRECTOR, Bristol-Myers Squibb
2026-07-03